维莫非尼治疗BRAFV600突变胶质瘤:VE-BASKET研究结果
确认客观缓解率为25%(95%CI 10%至47%),中位无进展生存期5.5个月(95%CI 3.7至9.6个月),安全性总体与既往研究一致。
要点
- 维莫非尼在部分BRAFV600突变胶质瘤患者中显示持久抗肿瘤活性。
- 疗效在不同组织学亚型间似乎存在定性差异。
- 需进一步研究确定维莫非尼在中枢神经系统原发肿瘤中的最佳使用。
核心结论
- 维莫非尼在部分BRAFV600突变胶质瘤患者中显示持久抗肿瘤活性,但疗效在不同组织学亚型间似乎存在定性差异。
研究设计与样本
- VE-BASKET研究为开放标签、非随机、多队列研究,针对BRAFV600突变非黑色素瘤癌症。
- 患者中位年龄32岁,女性18例、男性6例;包括恶性弥漫性胶质瘤11例(胶质母细胞瘤6例、间变性星形细胞瘤5例)、多形性黄色星形细胞瘤7例、间变性节细胞胶质瘤3例、毛细胞型星形细胞瘤2例、高级别胶质瘤非特指1例。
主要发现
- 确认客观缓解率为25%(95%CI 10%至47%),中位无进展生存期为5.5个月(95%CI 3.7至9.6个月)。
- 恶性弥漫性胶质瘤中,最佳缓解包括1例部分缓解和5例疾病稳定,其中2例疾病稳定持续超过1年。
- 多形性黄色星形细胞瘤中,最佳缓解包括1例完全缓解、2例部分缓解和3例疾病稳定。
- 毛细胞型星形细胞瘤和间变性节细胞胶质瘤各观察到1例部分缓解。
- 维莫非尼的安全性特征与既往发表研究总体一致。
临床怎么用
- 对于BRAFV600突变胶质瘤患者,维莫非尼可作为潜在治疗选择,但需注意疗效因组织学亚型而异。
- 治疗期间应监测疾病进展和不良反应,安全性管理参照既往维莫非尼研究经验。
局限性
- 疗效在不同组织学亚型间的差异机制尚不明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: BRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAFV600, in patients with gliomas that harbor this mutation. PATIENTS AND METHODS: The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAFV600-mutant nonmelanoma cancers. Patients with BRAFV600-mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects. Key end points included confirmed objective response rate by RECIST version 1.1, progression-free survival, overall survival, and safety. RESULTS: Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma), PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high-grade glioma, not otherwise specified (n = 1), were treated. Confirmed objective response rate was 25% (95% CI, 10% to 47%) and median progression-free survival was 5.5 months (95% CI, 3.7 to 9.6 months). In malignant diffuse glioma, best response included one partial response and five patients with stable disease, two of whom had disease stabilization that lasted more than 1 year. In PXA, best response included one complete response, two partial responses, and three patients with stable disease. Additional partial responses were observed in patients with pilocytic astrocytoma and anaplastic ganglioglioma (one each). The safety profile of vemurafenib was generally consistent with that of previously published studies. CONCLUSION: Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets.
引用
- Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol. 2018. PMID: 30351999. doi:10.1200/JCO.2018.78.9990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。